 2020 Q3 Earnings Call Summary

Chemed Corporation reported its Q3 2020 results, with hospice operations being impacted by the pandemic, but showing improvement as the federal government provided support and regulations were relaxed. Roto-Rooter services demand showed significant improvement in the second and third quarters, with commercial demand declining 11.6% in Q3 when compared to the prior year quarter, an improvement from the 29.1% decline in Q2. VITAS is estimated to achieve full year 2020 revenue growth of 12.5% to 13%, with Medicare Cap billing limitations estimated to be $8.6 million for calendar year 2020. Chemed's full year 2020 adjusted earnings per diluted share, excluding non-cash expense for stock options, tax benefits for stock options, costs related to litigation and other discrete items, is estimated to be in the range of $18 to $18.15, an improvement from the previous guidance of $16.20 to $16.40. The company is confident in its ability to support its team members and deliver care safely, with sufficient PPE inventory, education, and clinical protocols.